Introduction {#s1}
============

Stroke is the third leading cause of death in the USA, and its prevalence is increasing.[@R1] Our demographic findings include an increase in the elderly age category of greater than 65 years of age, with a corresponding increase in the prevalence of stroke in the elderly.[@R4] With advances in intra-arterial and mechanical thrombolysis, the interventional window was first extended to 8 h. Recently, the use of CT perfusion (CTP) has supported multimodal recanalization beyond 8 h. As a result, more elderly patients are participating in endovascular treatment of acute ischemic stroke.[@R5] CTP supports interventions in late diagnosis and distant referrals from stroke centers lacking in neurointerventional resources.[@R6]

Intuitively, minimally invasive treatment would seem to be better tolerated in the elderly population, but data have not supported this hypothesis to date. Also, endovascular intervention in the elderly suffering from acute ischemic stroke has not been thoroughly investigated. Kim *et al*[@R7] in a retrospective study comparing 31 elderly patients undergoing intra-arterial thrombolysis with a cohort of less than 80 years old, found no significant differences in recanalization or intracerebral hemorrhage, although a lower rate of survival and excellent outcome was noted in the elderly group. Similarly, Loh *et al*[@R8] found a higher likelihood of death among the elderly cohort after recanalization, with similar rates of recanalization and intracranial hemorrhage. Quereshi *et al*[@R9] in a pooled analysis of four prospective studies of thrombolysis in the elderly found in 24 patients a lower likelihood of recanalization and favorable outcome (modified Rankin Scale (mRS) score 0--2) along with increased mortality rates.

Elderly patient populations need to be studied with regard to interventional stroke care to determine if traditional therapies can be carried out without added risk. Angioplasty and stenting are increasingly performed alongside mechanical and chemical thrombolysis to maximize recanalization and improve flow restoration, with favorable results[@R10] Previous studies were limited by their small sample size. We assessed the safety and efficacy of multimodal endovascular recanalization in series of 51 patients aged ≥75 years who were treated in our institution.

Methods {#s2}
=======

Institutional review board approval was obtained. A retrospective chart review was conducted to include patients over the age of 75 years who were treated for acute ischemic stroke in our institution during the period 2009--2012. All patients underwent initial neurological assessment. Preoperative evaluation included a non-contrast head CT, which provided a baseline and excluded patients with intracranial hemorrhage or completed infarctions. In the period between 2006 and 2012, all patients underwent additional emergent CT angiography and CTP studies. The decision to proceed with endovascular thrombolysis was determined based on clinical and radiographic analysis of preoperative data. Inclusion criteria for intervention were a minimum National Institutes of Health Stroke Scale score of 8, CTP with ischemic penumbra on mean transient time and cerebral blood flow but preservation of cerebral blood volume, and detectable arterial occlusion on CT angiography. All arterial occlusions were confirmed by subsequent digital subtraction angiography. CTP has seen increased popularity for rapid assessment of candidates for endovascular intervention although its routine use in clinical practice is still under debate.[@R13]

Analysis of patient data included inpatient hospital records, imaging studies, operative reports and outpatient office records. Patient demographics, admission and discharge neurological examinations, medical comorbidities, such as prior history of hypertension, diabetes, stroke and smoking, and treatment complications were recorded and analyzed. Clinical outcome was evaluated at time of discharge using the mRS.

A total of 51 patients met the clinical and radiographic criteria and underwent multimodal endovascular recanalization for acute ischemic events. Postoperative course was assessed by MRI evaluation of stroke territory, incidence of intracranial hemorrhage and clinical neurological outcome on discharge. All CT and MRI data were evaluated by staff neuroradiologists. Thrombolysis in Myocardial Infarction (TIMI) scores were classified as follows: TIMI 0, no flow beyond the thrombus; TIMI 1, penetrance beyond the thrombus but without perfusion; TIMI 2, delayed perfusion; TIMI 3, normal perfusion beyond the thrombus. Time to intervention was defined as time from symptom onset to groin puncture.

Data acquired were analyzed by the Mann-Whitney U test and χ^2^ analysis where appropriate, using a statistical software package (MedCalc V.12.2.1.0 Mariakerke, Belgium).

Endovascular treatment {#s2a}
----------------------

Endovascular procedures occurred under general endotracheal anesthesia. Digital subtraction angiography of the affected carotid circulation was performed. An 8 French sheath and an 8 French guide catheter were used in most cases. An SL-10 (Stryker, Fremont, California, USA) and Synchro-14 microguidewire (Stryker) were used to cross the occluded arterial segment and determine the extent of the thrombus. Proximal internal carotid artery (ICA) occlusions were revascularized with balloon angioplasty with Viatrac (Abbott, Santa Clara, California, USA) and Aviator (Cordis, Bridgewater, New Jersey, USA) balloons. Off-label use of proximal carotid stenting was achieved with Precise (Cordis), Acculink (Abbott) and Guidant (Boston Scientific, Natick, Massachusetts, USA) stents. Once the cervical carotid circulation was re-established, angiography was repeated to assess the intracerebral circulation. If a tandem occlusion was seen in the intracranial circulation, mechanical thrombolysis was undertaken via a Merci Retriever (Concentric Medical, Mountainview, California, USA), Penumbra System (Penumbra Inc, Alameda, California, USA) (n=3), Hyperglide balloon (EV3, Irvine, California, USA) and Gateway balloon (Stryker). If mechanical thrombolysis was unsuccessful and ictus was within 8 h, pharmacologic thrombolysis was performed with intra-arterial tissue plasminogen activator, urokinase or ReoPro. The use of arterial thrombolytics has shifted throughout the time period reported. Urokinase was predominantly utilized in 2006 but has seen a steady decline in its use in favor of tissue plasminogen activator. For thrombi that are resistant to lytics, ReoPro was sometimes used at the discretion of the interventionalist. Additional intracranial stenting for tandem middle cerebral artery occlusions was performed with Wingspan (Stryker) and Enterprise (Cordis) stenting. The off-label use of the Enterprise stent has gained popularity for stroke intervention, due to its improved navigability and ease of deployment in various vessel anatomy (often not navigable with the Wingspan).[@R26] Finally, in all patients, post thrombolysis cerebral angiography was repeated to assess the patency of the extracranial and intracranial carotid circulation.

Postoperative management {#s2b}
------------------------

Postoperatively, all patients were transferred to the neurointensive care unit for a minimum of 24 h, after which a non-contrast head CT was routinely performed. All patients who underwent stent assisted revascularization and had no contraindication to antiplatelet therapy received 75 mg of clopidogrel daily for 6 weeks, as well as 81 mg of aspirin daily, which was continued indefinitely.

Results {#s3}
=======

All patients underwent cerebral angiography and met the angiographic criteria for endovascular thrombolysis. There were 35 women and 16 men with a mean age of 81.4 years (range 75--90 years). Thirty-four patients (67%) were \>80 years of age. Thirty-one (60.8%) patients had arterial hypertension, 23 (45.1%) had hypercholesterolemia, 12 (23.5%) had diabetes mellitus, 23 (45.1%) had atrial fibrillation and seven (13.7%) were active smokers. Mean National Institutes of Health Stroke Scale score was 17.1. The middle cerebral artery was occluded in 39 (76.5%) patients, the ICA in 10 (19.6%) patients and the basilar artery in two (3.9%) patients. Twenty-three patients (45%) received intravenous tissue plasminogen activator prior to admission. Mean time from symptom onset to endovascular intervention was 6.1 h. In 41 patients (80.4%), more than one endovascular treatment modality was employed (tables 1 and 2). The penumbra device was used in 23 patients, the Merci device in nine and both devices in 13. Eight (16%) patients underwent stent placement, 10 (20%) underwent balloon angioplasty and seven (14%) underwent both angioplasty and stent placement. Twenty-one (41%) patients required intra-arterial thrombolytics. At baseline, 46 (90.2%) patients had a TIMI score of 0 or 1(mean TIMI score was 0.19). An improvement in TIMI score was noted in 34 patients (67%). In 51 patients, post-recanalization TIMI scores were 0 in 11 (21.5%) patients, 1 in seven (13.7%) patients, 2 in 14 (27.5%) patients and 3 in 19 (37.3%) patients. A total of 13 (25.4%) patients demonstrated some degree of intracranial hemorrhage on postoperative imaging. Nine of 13 hemorrhages were confluent hematomas (PH-1 and PH-2, by the ECASS (European Cooperative Acute Stroke Study) classification).[@R27] Symptomatic intracranial hemorrhage occurred in three patients (6%) but did not require surgical intervention. One patient (1.9%) had a postoperative retroperitoneal hematoma, which was managed conservatively. There were two fatalities in our series from intraoperative vessel rupture (3.9%). The average length of stay was 11.8 days (1--32). At time of discharge, 33.3% of patients had a favorable outcome (mRS score 0--3). The average mRS score was 3.9. The all cause death rate was 21.6% in the series.

###### 

Patient characteristics

  Age (years)   IV tPA   Lesion location on angiogram   NIHSS on admission   Endovascular intervention       IA lytics   TIMI grade
  ------------- -------- ------------------------------ -------------------- ------------------------------- ----------- ------------
  81            N        R M1                           16                   IA lytics                       Y           2
  88            Y        R M1 M2                        17                   IA lytics                       Y           2
  84            N        Basilar                        10                   Stent                           Y           3
  78            Y        R M1                           19                   Balloon angioplasty             N           2
  85            Y        L M1                           15                   Stent                           Y           2
  90            N        R ICA                          17                   Balloon angioplasty             Y           0
  87            Y        R MCA, R ACA                   11                   Stent and balloon angioplasty   Y           3
  77            Y        R MCA                          22                   Stent                           Y           0
  81            Y        L ICA, supraclinoid            21                   IA lytics                       N           2
  84            N        R M1                           14                   IA lytics                       Y           3
  87            Y        L ICA, L PCA                   22                   Stent                           N           0
  84            N        L ICA                          13                   Stent and balloon angioplasty   N           3
  88            N        L MCA                          20                   Stent                           N           0
  76            N        L M1                           26                   IA lytics                       Y           1
  79            N        R M1                           20                   IA lytics                       Y           0
  84            Y        R M1                           17                   IA lytics                       N           2
  82            N        L ICA stenosis                 21                   IA lytics                       N           2
  80            Y        L ICA, L M1                    15                   Stent                           Y           3
  78            Y        R M1                           11                   Stent                           Y           2
  82            N        R MCA                          14                   IA lytics                       N           0
  81            N        R M1                           22                   IA lytics                       Y           2
  81            N        R M1                           11                   IA lytics                       N           3
  86            N        R ICA, R MCA                   10                   Stent                           N           0
  87            N        L ICA, L MCA                   16                   IA lytics                       Y           3
  84            N        L M1                           11                   IA lytics                       N           2
  77            Y        R M1                           14                   IA lytics                       N           3
  88            N        L MCA                          20                   IA lytics                       N           0
  76            N        L MCA                          21                   IA lytics                       Y           2
  82            N        R M2                           14                   IA lytics                       N           0
  75            Y        L M2                           22                   Balloon angioplasty             N           3
  83            Y        R MCA                          11                   IA lytics                       N           3
  85            N        R MCA                          8                    Balloon angioplasty             Y           1
  77            N        L MCA                          18                   IA lytics                       Y           3
  79            N        R MCA                          28                   Balloon angioplasty             Y           2
  83            N        R ICA                          18                   IA lytics                       N           0
  75            Y        L MCA                          12                   IA lytics                       Y           2
  82            Y        L MCA                          16                   Stent and balloon angioplasty   Y           3
  80            Y        L MCA                          19                   Stent and balloon angioplasty   N           2
  81            Y        L MCA                          14                   Stent and balloon angioplasty   N           1
  87            Y        L M1                           27                   Stent and balloon angioplasty   N           3
  78            Y        R ICA                          9                    Balloon angioplasty             N           2
  83            N        R ICA                          8                    IA lytics                       N           3
  75            Y        L MCA                          9                    Stent and balloon angioplasty   Y           3
  75            Y        R ICA                          15                   Balloon angioplasty             Y           3

ACA, anterior cerebral artery; IA, intra-arterial; ICA, internal carotid artery; IV tPA, intravenous tissue plasminogen activator; L, left; MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; PCA, posterior cerebral artery; R, right; TIMI, Thrombolysis in Myocardial Infarction.

###### 

Baseline characteristics

                          Total   Age \<80 years   Age \>80 years   p Value
  ----------------------- ------- ---------------- ---------------- ---------
  Male (n (%))            14      6                8                0.95
  Female (n (%))          37      11               26               0.06
  Atrial fibrillation     23      4                19               0.04
  Diabetes                12      3                9                0.38
  Hypertension            31      23               8                0.04
  IV tPA                  23      10               13               0.8
  NIHSS                           17.8             15.7             0.81
  Time intervention (h)           6                6.8              0.18

NIHSS, National Institute of Health Stroke Scale; IV tPA, intravenous tissue plasminogen activator.

Discussion {#s4}
==========

Acute ischemic stroke is the third leading cause of death in the USA and the most prevalent neurologic diagnosis. It is also the most common diagnosis in nursing home residents. With advancements in medicine and prolongation of life expectancy, stroke commonly affects the elderly. Unfortunately, there are minimal data to support acute endovascular intervention in this patient population. Additional studies are currently underway with the recent publication of the Thrombolysis in Elderly Stroke Patients in Italy (TESPI), a randomized, controlled trial evaluating intravenous tissue plasminogen activator versus standardized medical therapy in patients \>80 years of age, which is currently underway.[@R28]

Existing medical comorbidities such as diabetes, hypertension, cardiac history and renal insufficiency increase perioperative patient risk. Furthermore, vascular anatomical limitations, such as diffuse atherosclerosis, vessel tortuosity and peripheral vascular disease, pose additional surgical risks in the elderly. Yet, rapid reperfusion of the cerebral penumbra remains the gold standard in acute stroke care. The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) supported the notion that ICA stenting is comparable with carotid endarterecomy in terms of perioperative morbidity and mortality after 30 day and 2.5 year follow-ups.[@R28] Later analysis of the CREST data suggested a correlation between increasing age and risk of stroke.[@R28] [@R29]

In our series, we investigated the safety and efficacy of multimodality endovascular intervention for acute ischemic stroke in septuagenarians and above. Due to the high surgical risk in this patient population, careful inclusion criteria were set. The angiographic revascularization rates were good, with a mean TIMI score of 2 post-recanalization, with 34 patients (67%) achieving TIMI scores of 2 or greater. Perioperative morbidity was 27.5%, due to 13 intracranial and one retroperitoneal hemorrhage. Only three (5.8%) of the 13 intracranial hemorrhages were symptomatic. This was less than half the reported rate of symptomatic intracranial hemorrhage in an analysis of the PROACT II (Prolyse in Acute Cerebral Thromboembolism II) study.[@R30] In the aforementioned study, blood glucose \>200 mg/dl was associated with a 36% increased risk of intracranial hemorrhage. The prevalence of diabetes type I or II was higher in our population (23.5%), but in our case, this did not increase the rate of hemorrhage. The addition of angioplasty and or stent placement did not appear to have an impact on the overall incidence of intracranial hemorrhage, despite the need for clopidogrel post-intervention. Thirty-four per cent of patients underwent stent placement. While off-label, stent placement has increasingly been performed in acute stroke, to maximize flow restoration, with favorable results.[@R10] [@R31] In the non-operative population, hemorrhagic conversion has been reported to range from 15% to as high as 43%.[@R34] Our procedural death rate was 3.9%, which was due to vessel rupture, as evidenced by contrast extravasation intraoperatively. In previous series of elderly patients, time from ictus to endovascular intervention ranged from a mean of 4.3 to 6.25 h.[@R21] [@R35] Our study had an average time to intervention of 6.1 h. As a tertiary referral center, most patients at our center are evaluated at an outside institution and then transferred on clinical suspicion of stroke. The use of CTP criteria (which allowed the extension of the therapeutic window) to select patients for endovascular intervention also explains the long interval from stroke onset in our study.

Recently, Galimanis *et al* prospectively followed 623 patients who underwent endovascular recanalization for stroke. They concluded that 'time to treat' was the only significant factor leading to a better outcome.[@R36] Of one of the largest series to date involving multimodal recanalization, they found a 5.5% incidence of symptomatic intracranial hemorrhage. Qureshi *et al*[@R9] in his study of patients over 80 years old found a rate of 12% intracranial hemorrhage. We found 13 hemorrhages (25.4%) on postoperative routine imaging. Almost half of these patients had stent placement. A similarly high rate of hemorrhage was also reported by Loh *et al*[@R8] (61%). Difficulty arises in comparing rates of hemorrhage after intervention for a number of reasons. In our series, the added risk of hemorrhage from stent placement is unknown. Most importantly, 45% of our elderly cohort received intravenous tissue plasminogen activator prior to treatment, compared with 13% in the series by Qureshi and 35% by Loh *et al*[@R8] (intra-arterial and intravenous combined). Use of intra-arterial lytics to date has not used a standardized dose, which also does not allow for an even comparison across these three studies. Lastly, Loh *et al* utilized thrombectomy in all of their patients, without the use of stent. The observed morbidity and mortality in our study (21%) compares favorably with those of Qureshi *et al* (54%) and Loh *et al*[@R8] (48%).

The goal of stent placement in the setting of acute ischemic stroke is recanalization of the occluded vessel. Recanalization has been shown by Rha *et al*[@R37] to have a favorable clinical impact on meta-analysis. A retrospective review of 115 patients by Al-Ali *et al* showed that angioplasty had a lower 1 year risk of recurrent or new stroke than medical management with warfarin and aspirin. In their study, the risk of stroke was very similar when comparing bare metal stent to medical management (19% vs 18%, respectively).[@R38] Stenting for flow restoration in stroke is feasible with high rates of recanalization.[@R5] Stampfl *et al* showed successful recanalization with stenting in 89% in acute stroke.[@R5] Brekenfield *et al* followed prospectively 40 consecutive patients with acute ischemic stroke; 43% of patients underwent Wingspan (Boston Scientific) stenting and 57% of patients underwent thrombectomy alone with the Solitaire FR revascularization device (ev3, Plymouth, Minnesota, USA). Median ages were comparable (66 and 68 years in the two groups, respectively). The stented group showed superior rates of recanalization, and earlier time to flow restoration is seen, which were statistically significant.[@R39] Compared with thrombolysis alone, stent placement demonstrated higher rates of recanalization as well as comparable morbidity.[@R40]

The median age in this group was 81 years. One would expect a higher morbidity when the results of stroke studies are translated clinically. Stenting requires a minimum vessel compliance to achieve vessel recanalization safely. In human studies, Van Lammeren *et al*[@R41] harvested 1385 carotid plaques following endarterectomies, finding a correlation between larger more calcified plaques among the elderly. They showed that plaque stability decreased with age. Consequently, the endovascular risk during mechanical thrombolysis in the elderly may be higher than in the general population. In our patient group, two patients died as a result of intraoperative rupture following balloon angioplasty of the distal cervical ICA. Despite the advanced age in our series, our combined morbidity and mortality of 27.5% in the practice of multimodal recanalization did not differ significantly from that reported in younger patients.[@R9] Mathews *et al*[@R42] reviewed 94 consecutive patients who underwent endovascular therapy after ischemic stroke and found a combined morbidity and mortality of 26.6%. Again, given the lack of standardization in new interventional techniques, comparing results across studies poses a challenge.

On discharge, 17 patients (33%) had an mRS score of equal or less than 3, compared with 29% and 16% found by Loh[@R18] and Qureshi[@R20] on discharge, respectively. While the mean age of the patient population was \>80 years, 17 patients were between the ages of 75 and 80 years. As our series had equivalent to better outcomes than those previously reported, this potential bias should be noted. In fact, we felt that choosing an arbitrary cut-off of 75 as opposed to 80 years would provide a larger patient population for study. The number of patients older than 80 years (n=34) still comprises 67% of our patient population and therefore the results should be easily compared with existing studies.

General anesthesia during acute stroke intervention is standard practice at our institution at present. Recent literature raises the concern that general anesthesia may worsen neurologic outcomes, or even increase morbidity and mortality, compared with conscious sedation for endovascular recanalization.[@R43] [@R44] However, these observations were reported by retrospective studies and thus require confirmation by large prospective randomized studies. Our study has some limitation pertaining to its retrospective design and the absence of a control group (younger patients). We recognize that given the increased risks associated with endovascular treatment in this age group and the strict inclusion criteria for intervention, the patient population is rather small. Assessing outcome at discharge may also not reflect ultimate patient outcome. As mentioned previously, given the single institutional nature of this study, results are interpretable mainly to specific protocols utilized at this institution. Use of angioplasty and stenting must also be considered when interpreting results. Larger prospective randomized studies are required to investigate acute stroke interventions in this patient population, as little exists in the literature.

Conclusion {#s5}
==========

Multimodal endovascular recanalization of acute ischemic stroke is a safe treatment option in patients \>75 years of age. Careful patient selection by clinical and radiographic criteria is necessary for the successful management of stroke in this age group.
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